A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2

NACompletedINTERVENTIONAL
Enrollment

672

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

March 13, 2017

Study Completion Date

December 20, 2017

Conditions
Smoking
Interventions
OTHER

THS 2.2

Ad libitum use of THS 2.2 in an ambulatory setting for 26 weeks.

OTHER

CC

"Ad libitum use of CC in an ambulatory setting for 26 weeks.~The subject's own preferred brands of CC (no brand restriction) continue to be used as the reference product."

Trial Locations (19)

23294

National Clinical Research, Richmond

27518

PMG Research of Cary, Cary

27609

PMG Research of Raleigh, Raleigh

28209

PMG Research of Charlotte, Charlotte

28401

PMG Research of Wilmington, Wilmington

32117

Covance, Inc, Daytona Beach

32162

Compass Research, The Villages

32806

Compass Research, Orlando

33603

Clinical Research West Florida, Tampa

33765

Clinical Research West Florida, Clearwater

37620

PMG Research of Bristol, Bristol

37920

NOCCR, Knoxville

40509

Central Kentucky Research Associate, Lexington

45417

Midwest Clinical Research, Dayton

68502

Celerion Lincoln, Lincoln

76135

Benchmark, Fort Worth

76904

Benchmark, San Angelo

78705

Benchmark, Austin

85283

Celerion Arizona, Tempe

All Listed Sponsors
lead

Philip Morris Products S.A.

INDUSTRY

NCT02649556 - A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2 | Biotech Hunter | Biotech Hunter